Poulton Stuart 4

What Happened Stuart Poulton, EVP & Chief Development Officer of Karyopharm Therapeutics (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The RSUs were recorded at $0.00 per share (award/grant), meaning no cash was exchanged at grant. The RSUs convert into common stock on a one-for-one basis and are subject to time-based vesting.

Key Details

• Transaction date: 2026-01-31 (reported on Form 4 filed 2026-02-03; Period of Report: 2026-01-31)
• Transaction type/code: Award/Grant (A) — 32,415 RSUs @ $0.00 (no cash payment at grant)
• Vesting: 50% vest on 2027-01-31; remaining 50% vest on 2028-01-31 (per footnote)
• RSU conversion: Each RSU converts into one share of KPTI common stock upon vesting
• Shares owned after transaction: Not specified in the filing
• Filing timeliness: Form filed 2026-02-03; no late-filing flag indicated

Context This is a standard equity compensation grant to an executive (time-based RSUs). Grants are compensation and do not indicate an immediate purchase or sale of underlying shares; value to the insider is realized as the RSUs vest and convert to shares (and may be taxable upon vesting).